Our antibody oligonucleotide conjugate development services provide end-to-end support for pharmaceutical and biotech companies developing targeted AOC therapeutics. We combine antibody engineering, linker design, oligonucleotide chemistry, and advanced bioconjugation to deliver scalable, high-quality constructs for preclinical and early clinical programs.
We support a full range of bioconjugation strategies, including stochastic lysine and cysteine approaches as well as site-specific enzymatic, glycoconjugation, and click chemistry methods. These technologies enable precise control over conjugation, improving homogeneity, stability, and site-specific performance.
Our team designs and synthesizes both cleavable and non-cleavable linkers optimized for intracellular release and endosomal escape. We support multiple oligonucleotide modalities, including siRNA, antisense oligonucleotides, gapmers, and splice-switching oligos, with the ability to develop custom oligo chemistries and immune-modulating conjugates.
Our analytical platform provides comprehensive characterization, including DAR determination, conjugation-site analysis, free oligonucleotide quantification, oligo integrity, and nuclease and serum stability testing. Functional assays such as binding (EC50), internalization, endosomal escape, cytotoxicity, and PK/PD studies support candidate selection and mechanism validation.
We offer small-scale and pilot-scale (liter-scale) bioconjugation, along with cGMP payload and linker production where required. Our closed, automated workflows integrate conjugation, purification, and tangential flow filtration (TFF) into a single controlled process to improve efficiency, product consistency, and operator safety.
Our integrated CDMO model brings together antibody production, oligonucleotide synthesis, linker and payload development, conjugation, analytics, and fill-finish services in one streamlined workflow. This reduces transfer risk, shortens timelines, and simplifies supply chain complexity.
We also support method transfer and scale-up from early discovery through pilot batches and larger manufacturing. Our facilities and documentation are designed to meet regulatory expectations and support clinical supply and program progression.